Riptide Bioscience

Executive Summary

Riptide Bioscience is a private biotechnology company based in San Diego, focused on developing novel host defense peptides (HDPs) to combat microbial infections, particularly in wound and burn settings. HDPs are small proteins naturally occurring in humans and other organisms that act as a first line of defense against pathogens. The company's platform aims to harness these peptides to create new antimicrobial therapies, addressing the growing threat of antibiotic resistance. Founded in 2012, Riptide Bioscience leverages evolutionary conserved mechanisms to develop medicines with lifesaving potential. While the company remains in early stages without disclosed financials or clinical programs, its approach targets an urgent unmet medical need in chronic wound infections and burn care. The company's private status and limited public information suggest a pre-revenue, preclinical to clinical-stage pipeline, with potential for future partnerships or funding rounds to advance its lead candidates.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 1 clinical trial for lead HDP candidate30% success
• Q2 2026Announcement of Series A/B financing round50% success
• Q4 2026Publication of preclinical efficacy data in peer-reviewed journal60% success